Cedara wins some, loses some
Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an
Toronto-based Cedara introduced a new orthopedics desk application July 16. Earlier in the month, the company announced a deal with a major Chinese OEM to supply a user interface for its x-ray products. The good news came, however, on the heels of an announcement that the company has been delisted from the Nasdaq effective July 7.
The newly released Cedara OrthoWorks is a suite of desktop and Web server software solutions designed for orthopedic surgeons. The product allows instant access to digital patient images, surgical planning aids, measurement tools, and a library of digital prosthetic templates.
The product release followed a July 7 announcement that Shan Dong XinHua Medical, one of the largest medical equipment manufacturers in China, will integrate its new x-ray systems with Cedara's I-Acquire DR universal acquisition console application. The Cedara technology allows the acquisition of images from multiple digital detectors and x-ray generators from a single user interface.
Cedara stock is now being traded on the OTC Bulletin Board in the wake of its delisting from the Nasdaq. The move became necessary when Cedara was not able to meet the minimum shareholders' equity requirement. The company's listing on the Toronto Stock Exchange, where most of its shares have historically traded, was not affected.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
